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gocytosis, in keeping with diagnostic criteria of HLH.
Among the numerous causes of reactive hemo-
phagocytic processes, the main ones are lymphomas
and viral infections.3 The first case of VL revealed by
a reactive HLH was reported in an adult patient by
Matzner et al.5 The diagnosis of VL may be difficult
as clinical signs are similar in both VL and HLH.
Furthermore, serologic testing for Leishmania may
be negative at the onset of the disease.1 In a
recently reported French series of VL,6 the parasite
was not detected in 22% of cases. The reason for the
parasite scarcity in BM smears of patients with VL-
associated HLH is unclear. For our patient, Leishma-
nia was isolated only in peripheral blood culture,
and BM aspirate was negative for parasites at direct
microscopic examination and culture. Thus, diag-
nostic delays played an important role in the pro-
gressive fatal course of our patient’s disease.
Several therapeutic protocols are proposed in
HLH and depend on the type of hemophagocytic
syndrome. In reactive HLH associated with infec-
tion, supportive care and specific treatment of the
infection are associated with recovery in 60—70% of
cases.7 Thus, the causal therapy of leishmaniasis-
associated HLH is based on pentavalent antimonials
or amphotericin B, with corticosteroids.2
Liposomal amphotericin B seems most suitable
for VL-associated HLH, because lipid-associated
amphotericin B is taken up by macrophages and
targets the drug to the site of infection, leading
to very high concentration in the liver and spleen.1
Others drugs have been used when HLH is asso-
ciated with infectious disorders, such as intravenous
immunoglobulin, etoposide (which is cytotoxic
for macrophages), interferon alpha, corticoids,
thalidomide, cyclosporin, cyclophosphamide and
antilymphocyte serum.7
In conclusion, diagnosis of VL may be difficult,
when it is associated with hemophagocytosis.
Therefore, leishmaniasis should be considered when
discussing the cause of HLH in countries where the
disease is endemic, such as Tunisia. Early diagnosis
and appropriate treatment of VL are mandatory in
order to improve prognosis.
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23 June 2004Coccidioidal pericarditis
We recently presented a case report and review of
the literature concerning coccidioidal pericarditis
(CP).1 In all, 17 cases were described. During
the time between acceptance of this report andpublication an additional patient with CP has been
detailed and we believe it would be worthwhile to
highlight this case.
A 10 year-old African American girl presented
with chest discomfort and dyspnea. She was found
to have a left-sided pulmonary infiltrate and a large
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cultures confirmed coccidioidomycosis. Pericardio-
centesis revealed bloody fluid with a red cell count
of 1.1  1012/L, a white cell count of 9.6  109/L,
and a differential of 79% monocytes, 19% neutro-
phils, and 2% eosinophils. The protein was 6 g/dL,
and LDH was 1337 U/L (serum LDH, 248 U/L). Fungal
cultures from the fluid were negative. She was
treated with intravenous amphotericin B with reso-
lution of disease activity over a 12-month period,
and was subsequently placed on continuous treat-
ment with fluconazole 400 mg po, daily (verbal
communication, Crum NF). Surgical intervention
was not required and there has not been a relapse
over a 4-year follow-up period.2
This is the 18th case of CP in the medical litera-
ture. The presentation can be acute, progressing
rapidly to effusive—constrictive physiology or the
presentation can be that of a chronic constrictive
process. The current patient presented with chest
pain and dyspnea, a symptom complex similar to
previously reported patients with CP. What has not
been detailed previously is a bloody pericardial
effusion and female sex (presumably prepubertal).
The favorable outcome was also expected as the
patient did not have disseminated disease nor did
she develop pericardial constriction in need of sur-
gical intervention.
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3 March 2005Antibody response achieved by different rabies
prophylaxis methods
The incidence of human rabies in Turkey has
decreased significantly. In 2003, only one human
case was reported.1 There is a national rabies
prophylaxis guideline which is mostly based on
World Health Organization and the Advisory Com-
mittee on Immunization Practices recommenda-
tions.2,3 Post-exposure treatment including cell
culture vaccines and equine rabies immunoglobulin
(RIG) is free of charge. Human rabies immunoglo-
bulin (RIG) is very expensive and sometimes both
types of immunoglobulin are not readily available
when needed. In this study we compared the rabies
antibody titers achieved by two different post-
exposure prophylaxis regimens; RIG and five-dose
standard vaccination versus a 2-1-1-dose vaccina-
tion schedule.
Patients were selected from the outpatient clinic
of the Ankara Training and Research Hospital, Depart-
ment of Infectious Diseases and Clinical Microbiology,
admitted between September and December 2001.Patients bitten by a suspect animal were treated
according to the class of exposure described by the
Turkish Republic Ministry of Health Rabies Prophylaxis
Guidelines.4 Patients with class III exposure were
treated preferably with RIG (Rabies Antiserum Berna,
Switzerland) infiltratedaround thewounds and afive-
dose vaccination (Verorab, Pasteur-Merieux) on days
0, 3, 7, 14 and 28, (Group I). A 2-1-1-dose vaccination
schedule was applied to those patients where either
RIG could not be used orwho had been admitted from
an area of low endemic rabies, on days 0 (two doses,
different sites), 7 and 21 (Group II). Patients who had
an underlying disease or medication history or had
previously been vaccinated were excluded from the
study. Blood samples were collected, with the
patient’s permission, on the 7th and 30th days follow-
ing the first dose of vaccine. Serum rabies antibodies
were detected by ELISA (Platelia Rabies Kit, Bio-Rad,
France) according to themanufacturer’s instructions.
The cut-off value was 0.5 IU/ml.
There were 43 patients in Group I and 42 patients
in Group II. The results and some features of the
patients are shown in Table 1. Although the sero-
